Evidence map›Paper›PMID 40274951›Full record

ArticleScientific reports2025

Enhanced detection of glioblastoma vasculature with superparamagnetic iron oxide nanoparticles and MRI.

Phillip W Janowicz, Thomas Boele, Richard T Maschmeyer, Yaser H Gholami, Emma G Kempe, Brett W Stringer, Shihani P Stoner, Marie Zhang, Taymin du Toit-Thompson, Fern Williams and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Phillip W JanowiczImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. phillip.janowicz@sydney.edu.au.
Thomas BoeleImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Richard T MaschmeyerSchool of Physics, Faculty of Science, The University of Sydney, Sydney, Australia.
Yaser H GholamiSchool of Physics, Faculty of Science, The University of Sydney, Sydney, Australia.
Emma G KempeCharles Perkins Centre, The University of Sydney, Sydney, Australia.
Brett W StringerInstitute for Biomedicine and Glycomics, Griffith University, Brisbane, Australia.
Shihani P StonerBill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, Sydney, Australia.
Marie ZhangImagion Biosystems Ltd, Melbourne, Australia.
Taymin du Toit-ThompsonBill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, Sydney, Australia.
Fern WilliamsBill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, Sydney, Australia.
Aude TouffuBill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, Sydney, Australia.
Lenka MunozCharles Perkins Centre, The University of Sydney, Sydney, Australia.
Zdenka KuncicSchool of Physics, Faculty of Science, The University of Sydney, Sydney, Australia.
Caterina BrighiImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
David E J WaddingtonImage X Institute, Sydney School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. david.waddington@sydney.edu.au.

Funding

Cancer Institute NSW TPG2165National Health and Medical Research Council 1194004National Health and Medical Research Council 2017140
6 · The paper itself

Abstract

Detecting glioblastoma infiltration in the brain is challenging due to limited MRI contrast beyond the enhancing tumour core. This study aims to investigate the potential of superparamagnetic iron oxide nanoparticles (SPIONs) as contrast agents for improved detection of diffuse brain cancer. We examine the distribution and pharmacokinetics of SPIONs in glioblastoma models with intact and disrupted blood-brain barriers. Using MRI, we imaged RN1-luc and U87MG mice injected with Gadovist and SPIONs, observing differences in blood-brain barrier permeability. Peripheral imaging showed strong uptake of nanoparticles in the liver and spleen, while vascular and renal signals were transient. Susceptibility gradient mapping enabled positive nanoparticle contrast within tumours and provided additional information on tumour angiogenesis. This approach offers a novel method for detecting diffuse brain cancer. Our findings demonstrate that SPIONs enhance glioblastoma detection beyond conventional MRI, providing insights into tumour angiogenesis and opening new avenues for early diagnosis and targeted treatment strategies.

Indexed as

Brain NeoplasmsGlioblastomaMagnetic Iron Oxide NanoparticlesMagnetic Resonance ImagingMagnetite NanoparticlesNeovascularization, PathologicAnimalsBlood-Brain BarrierCell Line, TumorContrast MediaHumansMiceContrast MediaMagnetite NanoparticlesAngiogenesisBiodistributionContrast agentDetectionDiffuse glioblastomaFerumoxytolGlioblastomaMRIPEGPEGylationSPIONSusceptibilitySusceptibility gradient mapping

Identifiers

PMID40274951
PMCPMC12022243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.